QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Price Target Raised to $15 Following AVERSA Fentanyl Manufacturing Milestone
Nutriband (NASDAQ: NTRB) has received a new $15 price target in an updated report from Robert LeBoyer, Senior Vice President and Equity Research Analyst, Biotechnology, at Noble Capital Markets, following the successful completion of commercial manufacturing and scale-up for AVERSA Fentanyl, its abuse-deterrent transdermal patch developed in partnership with Kindeva. The report highlights this milestone as a key inflection point that enables Nutriband to initiate production of clinical supplies and proceed with its planned Investigational New Drug ("IND") application for a Phase 1 trial. The AVERSA program follows the 505(b)(2) regulatory pathway and requires only a single Phase 1 study,…